This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FOLD Amicus Therapeutics (FOLD) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock About Amicus Therapeutics Stock (NASDAQ:FOLD) Get Amicus Therapeutics alerts:Sign Up Key Stats Today's Range$14.49▼$14.5050-Day Range$14.33▼$14.4952-Week Range$5.51▼$14.50Volume5.29 million shsAverage Volume2.62 million shsMarket Capitalization$4.55 billionP/E RatioN/ADividend YieldN/APrice Target$14.56Consensus RatingHold Company Overview Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function. The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants. Beyond Fabry disease, Amicus is advancing a pipeline of investigational gene therapies and combination therapies, including programs targeting Pompe disease and Batten disease, with several candidates in late‐stage and mid‐stage clinical development. Founded in 2005 and headquartered in Cranbury, New Jersey, Amicus Therapeutics completed its initial public offering on the NASDAQ in 2015. The company maintains research and development operations in multiple locations across the United States and Europe, leveraging global manufacturing and regulatory expertise to support its clinical trials and commercial supply chain. Leadership at Amicus includes Chief Executive Officer Chirfi Guindo, who brings extensive experience in rare disease drug development, and John Crowley, co‐founder and Chairman of the Board. The company collaborates with leading pharmaceutical and academic partners to expand its platform and accelerate the development of novel therapies for underserved patient communities.AI Generated. May Contain Errors. Read More Amicus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks16th Percentile Overall ScoreFOLD MarketRank™: Amicus Therapeutics scored higher than 16% of companies evaluated by MarketBeat, and ranked 801st out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.3 / 5Analyst RatingHold Consensus RatingAmicus Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on no strong buy ratings, 2 buy ratings, 9 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Amicus Therapeutics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAmicus Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Amicus Therapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth79.07% Earnings GrowthEarnings for Amicus Therapeutics are expected to grow by 79.07% in the coming year, from $0.43 to $0.77 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amicus Therapeutics is -181.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amicus Therapeutics is -181.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmicus Therapeutics has a P/B Ratio of 16.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.14% of the float of Amicus Therapeutics has been sold short.Short Interest Ratio / Days to CoverAmicus Therapeutics has a short interest ratio ("days to cover") of 7.48.Change versus previous monthShort interest in Amicus Therapeutics has recently increased by 3.91%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmicus Therapeutics does not currently pay a dividend.Dividend GrowthAmicus Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Amicus Therapeutics this week, compared to 4 articles on an average week.Search Interest2 people have searched for FOLD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Amicus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Amicus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $322,875.00 in company stock.Percentage Held by Insiders2.20% of the stock of Amicus Therapeutics is held by insiders.Percentage Held by InstitutionsAmicus Therapeutics has minimal institutional ownership at this time.Read more about Amicus Therapeutics' insider trading history. Receive FOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FOLD Stock News HeadlinesJohn Paulson’s fund initiates Amicus Therapeutics position, dumps SOLS among Q1 movesMay 15, 2026 | msn.comAmicus Gains Final Approval for BioMarin Acquisition CompletionApril 26, 2026 | theglobeandmail.comThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession. The world's largest supercomputer requires power equipment that takes 120 weeks to build, and Musk built Colossus in just 122 days. One small American company is positioned to close that gap faster than anyone else, yet Wall Street still prices it like an afterthought. Dylan Jovine has the full story and the ticker.May 20 at 1:00 AM | Behind the Markets (Ad)CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)April 25, 2026 | fool.comAssessing Amicus Therapeutics (FOLD) Valuation After A Strong 71% One Year Total ReturnMarch 29, 2026 | finance.yahoo.comLeading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum CommunicationsMarch 26, 2026 | businesswire.comAssessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum And DCF UpsideMarch 15, 2026 | uk.finance.yahoo.comMicrosoft files amicus brief in support of Anthropic's lawsuit with US DODMarch 10, 2026 | reuters.comSee More Headlines FOLD Stock Analysis - Frequently Asked Questions How were Amicus Therapeutics' earnings last quarter? Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings results on Friday, February, 20th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by $0.03. Amicus Therapeutics's revenue was up 23.7% compared to the same quarter last year. Who are Amicus Therapeutics' major shareholders? Amicus Therapeutics' top institutional shareholders include Kryger Capital LLC (1.45%), Bank of America Corp DE (1.24%), Weiss Asset Management LP (1.23%) and Healthcare of Ontario Pension Plan Trust Fund (1.16%). Insiders that own company stock include Bradley L Campbell, Ellen Rosenberg, Ellen Rosenberg, Jeff Castelli, David Michael Clark, Samantha Prout and Margaret G Mcglynn. View institutional ownership trends. What other stocks do shareholders of Amicus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amicus Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Walt Disney (DIS), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and Netflix (NFLX). Company Calendar Last Earnings2/20/2026Today5/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 FOLD's financial health is in the Green zone, according to TradeSmith. FOLD has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:FOLD CIK1178879 Webwww.amicusrx.com Phone(215) 921-7600Fax609-662-2001Employees480Year Founded2002Price Target and Rating Average Price Target for Amicus Therapeutics$14.56 High Price Target$19.00 Low Price Target$11.00 Potential Upside/Downside+0.5%Consensus RatingHold Rating Score (0-4)2.08 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($0.08) Trailing P/E RatioN/A Forward P/E Ratio33.70 P/E GrowthN/ANet Income-$27.11 million Net Margins-4.27% Pretax Margin0.03% Return on Equity4.15% Return on Assets1.09% Debt Debt-to-Equity Ratio1.43 Current Ratio2.84 Quick Ratio1.88 Sales & Book Value Annual Sales$634.21 million Price / Sales7.17 Cash Flow$0.06 per share Price / Cash Flow234.67 Book Value$0.87 per share Price / Book16.66Miscellaneous Outstanding Shares314,000,000Free Float307,093,000Market Cap$4.55 billion OptionableOptionable Beta0.48 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:FOLD) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...Profits Run | SponsoredThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...Behind the Markets | SponsoredHe doesn't buy gold. He just profits from it.Former hedge fund manager Larry Benedict generated $274 million in profits - and Barron's ranked his fund in t...Brownstone Research | SponsoredHow to Access Elon’s “Monster” Interest RateMost Americans earn just 0.4% on their savings - that's $40 a year on $10,000. A new banking alternative is of...InvestorPlace | SponsoredThe “tell” for the end of the AI boomThe real question about AI stocks in 2026 isn't whether to own them - it's knowing exactly when to get in and ...Stansberry Research | SponsoredAfter June 1, don't say I didn't warn youMacroeconomic Strategist Dr. Mark Skousen of The Oxford Club says one date should be at the top of every inves...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
